Maternal and Fetal Outcomes with Metformin Therapy for Obese Pregnant Women A Randomized Control Trial

Aim of Work: To investigate the maternal and neonatal outcomes after using metformin among obese non diabetic Egyptian women. Study design: A case control, open label randomized controlled trial. Methods: A case control, open label randomized controlled trial study was conducted on 178 pregnant – 11 to 16 weeks – obese (Body mass index ≥ 30 kg/m 2 ) non diabetic females. Our populations` cohort were equally randomized into 2 groups, cases – who were subjected to receive metformin from the date of recruitment till termination of pregnancy – and controls – who received nothing – with follow up of the maternal glucose levels and documenting the maternal and fetal outcomes. Results: Metformin appeared to have a good patient acceptability with a less weight gain during enrollment of the trial among the pregnant females with a better glycemic control. There is no difference between the 2 groups regarding incidence of developing GDM, gestational hypertension and fetal macrosomia. Conclusion: Using metformin for obese non diabetic females, from the second trimester of pregnancy can reduce the maternal weight gain during pregnancy and provide a better glycemic control with no increase in perinatal and maternal complications.